Assessment of combination cardiac supplements available in the United States for dogs with myxomatous mitral valve disease

These results demonstrate the wide variety of CCC supplements marketed to dogs with MMVD and other cardiac diseases, as well as the large number of ingredients that have potential safety concerns, possible drug-supplement interactions, suboptimal doses, or limited supportive evidence.